Grifols SA (GRFS) Stock AnalysisGRFSStock AnalysisGrifols SA

Grifols SA is a Spain-based global specialty pharmaceutical company developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. The Company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use. It operates in the Healthcare sector.

Grifols is not a good buy right now due to several concerning factors. The current price is 7.69, and the stock has a low RSI of 32.945, indicating it is oversold. Additionally, the forward P/E ratio is 8.569, which is relatively low, but the company faces significant operational challenges, including regulatory restrictions in Canada that have affected its plasma centers. These issues could hinder future growth and profitability, making it a risky investment. Furthermore, hedge funds have increased selling by 986.97% over the last quarter, indicating a lack of confidence in the stock's near-term performance.

4 analysts cover GRFS: 3 rate it Buy, 0 Hold and 1 Sell.